The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans

Critical Care Medicine

Volumn 43, Issue 6, 2015, Pages e199-e202

  Van Der Meer, Anne J ^a   Scicluna, Brendon P ^a   Moerland, Perry D ^a   Lin, Jiang ^b   Jacobson, Eric W ^b   Vlasuk, George P ^b   Van Der Poll, Tom ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GLAXOSMITHKLINE   (United States)

Author keywords

blood coagulation; clinical trial; endotoxemia; inflammation; pharmaceutical preparations; sirtuin 1

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; ENDOTOXIN; ENZYME ACTIVATOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PROCOAGULANT; PROTHROMBIN; SIRTUIN 1; SRT 2104; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; CYTOKINE; FUSED HETEROCYCLIC RINGS; SRT2104;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; FIBRINOLYSIS; HUMAN; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM;

BLOOD COAGULATION; CYTOKINES; DOUBLE-BLIND METHOD; ENDOTOXINS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LIPOPOLYSACCHARIDES; MALE; SIRTUIN 1; YOUNG ADULT;

EID: 84937552833     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000949     Document Type: Article

References (10)

1. Xie J, Zhang X, Zhang L: Negative regulation of infammation by SIRT1. Pharmacol Res 2013; 67:60-67
2. Ng PY, Bemis JE, Vlasuk G P, et al.: The identification of the SIRT1 activator SRT2104 as a clinical candidate. Lett Drug Des Discov 2013; 10:793-797
3. Masri S, Sassone-Corsi P: Sirtuins and the circadian clock: bridging chromatin and metabolism. Sci Signal 2014; 7:re6
4. Hoffmann E, Wald J, Lavu S, et al: Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol 2013; 75:186-196
5. Yang H, Zhang W, Pan H, et al: SIRT1 activators suppress infamma-tory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS One 2012; 7:e46364
6. de Jonge E, Dekkers PE, Creasey AA, et al: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without infuencing the fbrinolytic and cytokine response during human endo-toxemia. Blood 2000; 95:1124-1129
7. Breitenstein A, Stein S, Holy EW, et al: Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res 2011; 89:464-472
8. Zhang QJ, Wang Z, Chen HZ, et al: Endothelium-specific overexpres-sion of class III deacetylase SIRT1 decreases atherosclerosis in apo-lipoprotein E-defcient mice. Cardiovasc Res 2008; 80:191-199
9. Calvano SE, Xiao W, Richards DR, et al; Infamm and Host Response to Injury Large Scale Collab. Res. Program: A network-based analysis of systemic infammation in humans. Nature 2005; 437:1032-1037
10. Mercken EM, Mitchell SJ, Martin-Montalvo A, et al: SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 2014; 13:787-796